---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-26-000077"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2026-08-05T11:05:09+00:00"
generated_at: "2026-08-05T11:10:52.264801+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lilly Q2 revenue up 48% to $23.0B; raises full-year guidance

## Summary
- Q2 2026 revenue $22,974M (+48% YoY); reported EPS $7.94 (+26%), non-GAAP EPS $8.38 (+33%).
- Full-year revenue guidance raised to $85.0-87.0B; non-GAAP EPS guidance $35.50-$36.50 (up $2.78 midpoint).
- Q2 EPS includes $3.03/share of acquired IPR&D charges from business development activity.
- Completed acquisitions of Orna, Ajax, Centessa, Kelonia; post-quarter added infectious disease assets and AtaiBeckley.
- Committed $4.5B to expand Indiana manufacturing sites; retatrutide Phase 3 data complete for global registrations.

## SEC filing metadata
- accession: 0000059478-26-000077
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2026-08-05T11:05:09+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/0000059478-26-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/lly-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-26-000077
- JSON: https://secwatch.observer/filing/0000059478-26-000077.json
- Plain text: https://secwatch.observer/filing/0000059478-26-000077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.